Evidence map›Paper›PMID 38279352›Full record

ArticleInternational journal of molecular sciences2024

The Risk Function of Breast and Ovarian Cancers in the Avrami-Dobrzyński Cellular Phase-Transition Model.

Anna Zawadzka, Beata Brzozowska, Anna Matyjanka, Michał Mikula, Joanna Reszczyńska, Adrianna Tartas, Krzysztof W Fornalski

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anna ZawadzkaMaria Skłodowska-Curie National Research Institute of Oncology (NIO-MSCI), 02-781 Warsaw, Poland.ORCID 0000-0003-0757-0869
Beata BrzozowskaFaculty of Physics, University of Warsaw, 02-093 Warsaw, Poland.ORCID 0000-0003-0247-697X
Anna MatyjankaFaculty of Physics, Warsaw University of Technology, 00-662 Warsaw, Poland.
Michał MikulaMaria Skłodowska-Curie National Research Institute of Oncology (NIO-MSCI), 02-781 Warsaw, Poland.ORCID 0000-0003-3447-7328
Joanna ReszczyńskaMossakowski Medical Research Institute, Polish Academy of Sciences (IMDiK PAN), 02-106 Warsaw, Poland.ORCID 0000-0002-3135-5387
Adrianna TartasFaculty of Physics, University of Warsaw, 02-093 Warsaw, Poland.
Krzysztof W FornalskiFaculty of Physics, Warsaw University of Technology, 00-662 Warsaw, Poland.ORCID 0000-0001-7452-0189

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Specifying the role of genetic mutations in cancer development is crucial for effective screening or targeted treatments for people with hereditary cancer predispositions. Our goal here is to find the relationship between a number of cancerogenic mutations and the probability of cancer induction over the lifetime of cancer patients. We believe that the Avrami-Dobrzyński biophysical model can be used to describe this mechanism. Therefore, clinical data from breast and ovarian cancer patients were used to validate this model of cancer induction, which is based on a purely physical concept of the phase-transition process with an analogy to the neoplastic transformation. The obtained values of model parameters established using clinical data confirm the hypothesis that the carcinogenic process strongly follows fractal dynamics. We found that the model's theoretical prediction and population clinical data slightly differed for patients with the age below 30 years old, and that might point to the existence of an ancillary protection mechanism against cancer development. Additionally, we reveal that the existing clinical data predict breast or ovarian cancers onset two years earlier for patients with

Indexed as

Breast NeoplasmsOvarian NeoplasmsAdultBRCA1 ProteinBRCA2 ProteinFemaleGenetic Predisposition to DiseaseHumansMutationBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanAvrami equationbreast cancercancercancer physicscarcinogenesisfractalneoplastic transformationovary cancerphase transition

Identifiers

PMID38279352
PMCPMC10816518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.